Eli Lilly reports 23.3% weight loss in Phase 2 trial of EloraTZP combination for type 2 diabetes
Eli Lilly disclosed Phase 2 data for its experimental combination EloraTZP, pairing eloralintide with tirzepatide. In a 48‑week trial of 367 adults with obesity and type 2 diabetes, the highest‑dose regimen produced an average 23.3% body‑weight loss, equivalent to about 54 lb, versus 14.8% (≈34 lb) with tirzepatide alone. The combination also lowered A1C by 2.9 percentage points, compared with 2.4 points for tirzepatide alone. Up to 27% of participants stopped the combination because of side effects.
Why it matters
Lilly expects to begin Phase 3 trials of a single‑injection version of EloraTZP by the end of 2026, aiming to confirm the weight‑loss benefit while reducing dropouts. If successful, the data could expand Lilly's cardiometabolic pipeline and offer a more potent obesity treatment for patients with type 2 diabetes.
Key facts
- 1The Phase 2 trial lasted 48 weeks and enrolled 367 adults in the United States and Argentina. medicaldaily.com
- 2The highest‑dose combination (eloralintide 9 mg + tirzepatide 15 mg) produced an average 23.3% weight loss, about 54 lb. medicaldaily.com
- 3Tirzepatide alone (15 mg) produced a 14.8% weight loss, about 34 lb. medicaldaily.com
- 4The combination lowered A1C by 2.9 percentage points, versus 2.4 points for tirzepatide alone. medicaldaily.com
- 5Up to 27% of participants on the combination discontinued due to side effects, compared with 2.9% on tirzepatide alone. medicaldaily.com
- 6Lilly plans to start Phase 3 trials of a single‑injection version of EloraTZP by the end of 2026. medicaldaily.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.